Microsoft President Brad Smith told CNBC’s Arjun Kharpal that U.S. tech companies should “worry a little bit” about the subsidies their Chinese competitors receive from their government in the AI race ...

CNBC Markets Now provides a look at the day's market moves with commentary and analysis from Michael Santoli, CNBC Senior Markets Commentator. Got a confidential news tip? We want to hear from you.

This is part of a series of CNBC Pro articles designed to help you make the most of your Pro membership and all that CNBC has to offer. While some investors are focused on qualitative factors, many ...

Andrew Parris saw a path to space. He’d entered a competition — his ninth — that would fly six people on Blue Origin’s suborbital rocket from West Texas. This competition wasn’t a random drawing. It ...

CNBC's Kelly Evans reports on the latest news. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...

The third annual CNBC Changemakers list recognizes women transforming business and philanthropy across sectors including energy, financial services, health care, media, retail, sports and technology.

Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. This week, I ...

A Florida federal judge appointed by President Donald Trump blocked the public release of a final report by former special counsel Jack Smith on his prosecution of Trump for retaining classified ...

This is part of a series of CNBC Pro articles designed to help you make the most of your Pro membership and all that CNBC has to offer. Free account benefits With a free account on CNBC.com or the ...

Update: The FDA reversed its decision on Feb. 18 and agreed to consider Moderna's application. Read the latest here. Our earlier story is below. The Food and Drug Administration is refusing to ...

Orlando Bravo, founder and managing partner at Thoma Bravo, joins 'Money Movers' to discuss the slump in software stocks. Got a confidential news tip? We want to hear from you. Sign up for free ...